The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Linezolid: a promising option in the treatment of Gram-positives
Open accessAbstract
Linezolid, an oxazolidinone antimicrobial agent that acts by inhibiting protein synthesis in a unique fashion, is used in the treatment of community-acquired pneumonia, skin and soft-tissue infections and other infections caused by Gram-positive bacteria including VRE and methicillin-resistant staphylococci. Currently, linezolid resistance among these pathogens remains low, commonly <1.0%, although the prevalence of antibiotic resistance is increasing in many countries. Therefore, the development of resistance by clinical isolates should prompt increased attention of clinical laboratories to routinely perform linezolid susceptibility testing for this important agent and should be taken into account when considering its therapeutic use. Considering the importance of linezolid in the treatment of infections caused by Gram-positive bacteria, this review was undertaken to optimize the clinical use of this antibiotic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toh, S., Xiong, L., Arias, C. A., Villegas, M. V., Lolans, K., Quinn, J., & Mankin, A. S. (2007) · Molecular Microbiology · doi:10.1111/j.1365-2958.2007.05744.x · Cited by 338
Mendes, R. E., Deshpande, L. M., & Jones, R. N. (2014) · Drug Resistance Updates · doi:10.1016/j.drup.2014.04.002 · Cited by 221
Tedizolid for the Management of Human Infections: In Vitro Characteristics
Locke, J. B., Zurenko, G. E., Shaw, K. J., & Bartizal, K. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit616 · Cited by 101
Response to Emerging Infection Leading to Outbreak of Linezolid-Resistant Enterococci
Kainer, M. A., Devasia, R. A., Jones, T. F., Simmons, B. P., Melton, K., Chow, S., Broyles, J., Moore, K. L., Craig, A. S., & Schaffner, W. (2007) · Emerging Infectious Diseases · doi:10.3201/eid1307.070019 · Cited by 96
Metadata
- Authors
- Zahedi Bialvaei, A., Rahbar, M., Yousefi, M., Asgharzadeh, M., & Samadi Kafil, H.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-12-20
- Volume
- 72
- Issue
- 2
- Pages
- 354-364
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2564499404
- Cited by
- 170
- References
- 4
- FWCI
- 8.96
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Linezolid: a promising option in the treatment of Gram-positives. https://app.cochat.ai/papers/10.1093/jac/dkw450
- The paper
- Zahedi Bialvaei, A., Rahbar, M., Yousefi, M., Asgharzadeh, M., & Samadi Kafil, H. (2017). Linezolid: a promising option in the treatment of Gram-positives. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkw450
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.